Stocks · News reference
Reported Sunday, Taiho And Cullinan's REZILIENT3 Trial Meets Primary Endpoint, Zipalertinib Combination Shows PFS Hazard Ratio Of 0.50 Versus Chemotherapy Alone
Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.
Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time
8-K filing — Cullinan Therapeutics, Inc. (CGEM)
Filed: 2026-10-02 AccNo: 0001193125-26-411011 Size: 195 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits